| Identification | Back Directory | [Name]
BI 703704 | [CAS]
1423067-48-4 | [Synonyms]
BI 703704
(Rac)-BI 703704
(Rac)BI 703704,(Rac) BI 703704
3-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[4-[5-methyl-2-[[2-methyl-4-(1-piperidinylcarbonyl)phenyl]methoxy]phenyl]-2-thiazolyl]- | [Molecular Formula]
C32H37N3O4S | [MDL Number]
MFCD32671339 | [MOL File]
1423067-48-4.mol | [Molecular Weight]
559.72 |
| Chemical Properties | Back Directory | [Boiling point ]
762.3±70.0 °C(Predicted) | [density ]
1.269±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.21±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy[1]. | [in vivo]
(Rac)-BI 703704 (0.3-10 mg/kg; food intake; daily for 15 weeks) inhibits the progression of diabetic nephropathy in the ZSF1 rat[1]. | Animal Model: | 12-13 weeks male ZSF1 obese rats[1] | | Dosage: | 0.3, 1, 3, or 10 mg/kg | | Administration: | Food intake; daily for 15 weeks | | Result: | Dose-dependent increased in renal cGMP levels; Dosedependent decreased in urinary protein excretion (UPE); Accompanied by a significant reduction in the incidence of glomerulosclerosis and interstitial lesions. |
| [References]
[1] Yu L, et al. Picrocrocin exhibits growth inhibitory effects against SKMEL- 2 human malignant melanoma cells by targeting JAK/ STAT5 signaling pathway, cell cycle arrest and mitochondrial mediated apoptosis. J BUON. 2018 Jul-Aug;23(4):1163-1168. PMID:30358226 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|